Cornerstone Robotics Ltd. raised an oversubscribed $200 million series D round to accelerate commercialization of its ...

In a deal worth up to $840 million, Third Arc Bio Inc. is licensing Adagene Inc.’s Safebody technology platform to generate ...

A251, a novel HER2 antibody-drug conjugate (ADC) designed to deliver a potent PI3K/PIKK inhibitor directly to tumor cells.

Merck & Co. Inc. is buying Cidara Therapeutics Inc. for $9.2 billion to acquire a late-stage flu candidate and also to ...

The U.S. Environmental Protection Agency has moved to relax reporting requirements for perfluoroalkyl and polyfluoroalkyl substances used in a variety of applications, including medical devices.

Siemens AG will deconsolidate its remaining 67% stake in Siemens Healthineers AG to a significant minority as it looks to ...

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Amsino International, Evonik, Inspira Technologies, Kelyniam Global, MEG Medical Equipment, ...

Numab Therapeutics AG and Kaken Pharmaceutical Co. Ltd. have entered into a strategic licensing and co-development agreement for NM-81, a multi-specific antibody for the treatment of inflammatory ...

Biopharma dealmaking activity remained strong in October, with total deal value reaching $31.86 billion, a 17% increase from $27.15 billion in September and ranking as the second-highest month in 2025 ...

Biopharma companies focused on infectious disease extended their stock recoveries through the third quarter (Q3), with the BioWorld Infectious Disease Index closing October up 28.98%. The gain marks a ...

During the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scientists from Plexium Inc. presented the identification of a new class of potent, selective, cereblon ...

In an effort to generate an effective and safer inhibitor, researchers at the University of Cape Town, University of Dundee and Massachusetts Institute of Technology used structure-guided rational ...